Abstract

Dr. Namrata Pawar, *Dr. Vasundhara Bhople, Dr. Suhaas Wighne and Dr. Uma Bhosale

ABSTRACT

Purpose: With the currently growing spread of the COVID-19 pandemic, its affective treatment is also a major concern for the medical fraternity. At present there are no proven effective therapies for COVID–19 and the vaccine is also not available yet. The current treatments mainly focus on symptomatic relief and respiratory support. Various pharmacological treatments are currently being tested for patients with COVID–19. The elderly population and patients with underlying disease are at high risk of severe illness from COVID–19.These patients were more prone to experience adverse events (AEs) due to the use of concomitant medications and limited knowledge and inappropriate promotion of unproven therapies by the media and certain public figures leading to some severe ADRs. Thus, quality pharmacovigilance has become more important than ever. Methods: An Observational, non-interventional, questionnaire-based study was conducted by the Department of Pharmacology in the COVID ward of SKNMC & GH, Pune. This was a questionnaire-based study including 12 questions on adverse effects experienced due to medication in Covid-19 positive patients. Results: Out of the total, about 14% of patients suffered from ADR due to COVID medications while 76% experienced no ADR and 10% didn’t know about any ADR. When asked about the severity of ADR; out of 14% of patients,6% wrote as they were having mild symptoms, 6% were moderate and 2% were severe. Conclusions: The study indicates that there are few ADRs related to the COVID 19 treatment. Those ADRs were not life-threatening ones.